Adverum Makes Job Cuts To Advance Wet AMD Gene Therapy
Moving On After Last Year's Safety Issues
The California-based biotech is reducing its workforce to help finance a Phase II study of Ixo-vec, its eye gene therapy which has been blighted by safety concerns.
